CXorf61 is a target for T cell based immunotherapy of triple-negative breast cancer. 2015

Claudia Paret, and Petra Simon, and Kirsten Vormbrock, and Christian Bender, and Anne Kölsch, and Andrea Breitkreuz, and Özlem Yildiz, and Tana Omokoko, and Stefanie Hubich-Rau, and Christoph Hartmann, and Sabine Häcker, and Meike Wagner, and Diana Barea Roldan, and Abderaouf Selmi, and Özlem Türeci, and Ugur Sahin
TRON gGmbH, Translational Oncology at the University Medical Center, Johannes Gutenberg-University, Mainz, Germany.

Triple-negative breast cancer (TNBC) is a high medical need disease with limited treatment options. CD8+ T cell-mediated immunotherapy may represent an attractive approach to address TNBC. The objectives of this study were to assess the expression of CXorf61 in TNBCs and healthy tissues and to evaluate its capability to induce T cell responses. We show by transcriptional profiling of a broad comprehensive set of normal human tissue that CXorf61 expression is strictly restricted to testis. 53% of TNBC patients express this antigen in at least 30% of their tumor cells. In CXorf61-negative breast cancer cell lines CXorf61 expression is activated by treatment with the hypomethylating agent 5-aza-2'-deoxycytidine. By vaccination of HLA-A*02-transgenic mice with CXorf61 encoding RNA we obtained high frequencies of CXorf61-specific T cells. Cloning and characterization of T cell receptors (TCRs) from responding T cells resulted in the identification of the two HLA-A*0201-restricted T cell epitopes CXorf6166-74 and CXorf6179-87. Furthermore, by in vitro priming of human CD8+ T cells derived from a healthy donor recognizing CXorf6166-74 we were able to induce a strong antigen-specific immune response and clone a human TCR recognizing this epitope. In summary, our data confirms this antigen as promising target for T cell based therapies.

UI MeSH Term Description Entries
D007115 Immunization Schedule Schedule giving optimum times usually for primary and/or secondary immunization. Immunization Schedules,Schedule, Immunization,Schedules, Immunization
D008822 Mice, Transgenic Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN. Transgenic Mice,Founder Mice, Transgenic,Mouse, Founder, Transgenic,Mouse, Transgenic,Mice, Transgenic Founder,Transgenic Founder Mice,Transgenic Mouse
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011948 Receptors, Antigen, T-Cell Molecules on the surface of T-lymphocytes that recognize and combine with antigens. The receptors are non-covalently associated with a complex of several polypeptides collectively called CD3 antigens (CD3 COMPLEX). Recognition of foreign antigen and the major histocompatibility complex is accomplished by a single heterodimeric antigen-receptor structure, composed of either alpha-beta (RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA) or gamma-delta (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA) chains. Antigen Receptors, T-Cell,T-Cell Receptors,Receptors, T-Cell Antigen,T-Cell Antigen Receptor,T-Cell Receptor,Antigen Receptor, T-Cell,Antigen Receptors, T Cell,Receptor, T-Cell,Receptor, T-Cell Antigen,Receptors, T Cell Antigen,Receptors, T-Cell,T Cell Antigen Receptor,T Cell Receptor,T Cell Receptors,T-Cell Antigen Receptors
D003001 Cloning, Molecular The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells. Molecular Cloning
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old

Related Publications

Claudia Paret, and Petra Simon, and Kirsten Vormbrock, and Christian Bender, and Anne Kölsch, and Andrea Breitkreuz, and Özlem Yildiz, and Tana Omokoko, and Stefanie Hubich-Rau, and Christoph Hartmann, and Sabine Häcker, and Meike Wagner, and Diana Barea Roldan, and Abderaouf Selmi, and Özlem Türeci, and Ugur Sahin
June 2012, Breast cancer research and treatment,
Claudia Paret, and Petra Simon, and Kirsten Vormbrock, and Christian Bender, and Anne Kölsch, and Andrea Breitkreuz, and Özlem Yildiz, and Tana Omokoko, and Stefanie Hubich-Rau, and Christoph Hartmann, and Sabine Häcker, and Meike Wagner, and Diana Barea Roldan, and Abderaouf Selmi, and Özlem Türeci, and Ugur Sahin
January 2023, Frontiers in cell and developmental biology,
Claudia Paret, and Petra Simon, and Kirsten Vormbrock, and Christian Bender, and Anne Kölsch, and Andrea Breitkreuz, and Özlem Yildiz, and Tana Omokoko, and Stefanie Hubich-Rau, and Christoph Hartmann, and Sabine Häcker, and Meike Wagner, and Diana Barea Roldan, and Abderaouf Selmi, and Özlem Türeci, and Ugur Sahin
May 2022, Clinical cancer research : an official journal of the American Association for Cancer Research,
Claudia Paret, and Petra Simon, and Kirsten Vormbrock, and Christian Bender, and Anne Kölsch, and Andrea Breitkreuz, and Özlem Yildiz, and Tana Omokoko, and Stefanie Hubich-Rau, and Christoph Hartmann, and Sabine Häcker, and Meike Wagner, and Diana Barea Roldan, and Abderaouf Selmi, and Özlem Türeci, and Ugur Sahin
November 2021, Pharmaceutics,
Claudia Paret, and Petra Simon, and Kirsten Vormbrock, and Christian Bender, and Anne Kölsch, and Andrea Breitkreuz, and Özlem Yildiz, and Tana Omokoko, and Stefanie Hubich-Rau, and Christoph Hartmann, and Sabine Häcker, and Meike Wagner, and Diana Barea Roldan, and Abderaouf Selmi, and Özlem Türeci, and Ugur Sahin
October 2010, Journal of the National Cancer Institute,
Claudia Paret, and Petra Simon, and Kirsten Vormbrock, and Christian Bender, and Anne Kölsch, and Andrea Breitkreuz, and Özlem Yildiz, and Tana Omokoko, and Stefanie Hubich-Rau, and Christoph Hartmann, and Sabine Häcker, and Meike Wagner, and Diana Barea Roldan, and Abderaouf Selmi, and Özlem Türeci, and Ugur Sahin
December 2014, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Claudia Paret, and Petra Simon, and Kirsten Vormbrock, and Christian Bender, and Anne Kölsch, and Andrea Breitkreuz, and Özlem Yildiz, and Tana Omokoko, and Stefanie Hubich-Rau, and Christoph Hartmann, and Sabine Häcker, and Meike Wagner, and Diana Barea Roldan, and Abderaouf Selmi, and Özlem Türeci, and Ugur Sahin
February 2020, Scientific reports,
Claudia Paret, and Petra Simon, and Kirsten Vormbrock, and Christian Bender, and Anne Kölsch, and Andrea Breitkreuz, and Özlem Yildiz, and Tana Omokoko, and Stefanie Hubich-Rau, and Christoph Hartmann, and Sabine Häcker, and Meike Wagner, and Diana Barea Roldan, and Abderaouf Selmi, and Özlem Türeci, and Ugur Sahin
August 2021, Pharmaceuticals (Basel, Switzerland),
Claudia Paret, and Petra Simon, and Kirsten Vormbrock, and Christian Bender, and Anne Kölsch, and Andrea Breitkreuz, and Özlem Yildiz, and Tana Omokoko, and Stefanie Hubich-Rau, and Christoph Hartmann, and Sabine Häcker, and Meike Wagner, and Diana Barea Roldan, and Abderaouf Selmi, and Özlem Türeci, and Ugur Sahin
January 2014, Anticancer research,
Claudia Paret, and Petra Simon, and Kirsten Vormbrock, and Christian Bender, and Anne Kölsch, and Andrea Breitkreuz, and Özlem Yildiz, and Tana Omokoko, and Stefanie Hubich-Rau, and Christoph Hartmann, and Sabine Häcker, and Meike Wagner, and Diana Barea Roldan, and Abderaouf Selmi, and Özlem Türeci, and Ugur Sahin
January 2021, Frontiers in oncology,
Copied contents to your clipboard!